Background-Depression predicts prognosis in many cardiac conditions, including congestive heart failure (CHF). Despite heightened cardiac risk in patients with comorbid atrial fibrillation (AF) and CHF, depression has not been studied in this group. This substudy, from the AF-CHF Trial of rate-versus rhythm-control strategies, investigated whether depression predicts long-term cardiovascular mortality in patients with left ventricular ejection fraction Յ35%, CHF symptoms, and AF history who receive optimal medical care.
A trial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 1% of the population, with its prevalence rising with age. 1 AF increases the risk of stroke, congestive heart failure (CHF), ventricular arrhythmias, and death, 1 including sudden death. 2 It has been estimated that CHF increases the risk of AF by a factor of 4.5 to 5.9, 1 with AF present in 10% to 50% of CHF patients. 3 However, it remains controversial whether or not comorbid AF-CHF results in an increased risk of mortality above the risk associated with CHF alone. 3 Furthermore, little is known about potentially treatable risk factors for mortality in this population. 4 
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Numerous studies have found that depression predicts prognosis in other cardiac conditions, including post-myo-cardial infarction, post-unstable angina, CHF, coronary artery bypass grafting, and stable coronary artery disease (CAD). 5, 6 There is also evidence that depression may be a risk factor for stroke, 7 ventricular arrhythmias, and sudden death. 8 Several pathophysiological mechanisms hypothesized to explain the link between depression and cardiac prognosis are also characteristic of CHF. 9 Finally, there is evidence that these mechanisms, including changes in platelet function, 10 endothelial function, 10, 11 inflammation, 12 and autonomic balance, 13 may play important roles in the origin and/or persistence of AF. Despite the evidence suggesting a potentially important role for depression, to the best of our knowledge, only 1 study has evaluated the prognostic importance of depression in AF patients, 14 and none has specifically investigated patients with comorbid AF and CHF.
The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial was a randomized trial of rate-versus rhythmcontrol strategies in patients with AF and CHF. 3 Before randomization, participants completed the Beck Depression Inventory-II (BDI-II), 15 a well-validated measure of depression symptoms. The purpose of the present study was to assess the prognostic importance of depression symptoms in patients with AF and CHF who received optimal medical management and to determine the extent to which baseline measures of disease severity accounted for any observed links between depression and outcome.
Methods

AF-CHF Trial
The AF-CHF trial methods have been described previously. 3, 16 Between May 2001 and June 2005, 1376 patients from 10 countries were randomly assigned to rate-or rhythm-control strategies. The study protocol was approved by institutional review boards at each site. Eligibility criteria included left ventricular ejection fraction Յ35% within the past 6 months, history of symptomatic CHF, history of AF with ECG documentation within the past 6 months, and eligibility for treatment with both the rhythm-and rate-control strategies. Patients were excluded if they were expected to live Ͻ1 year, had persistent AF for Ͼ12 months, were slated for heart transplantation within 6 months, experienced decompensated heart failure in the 48 hours before randomization, had other arrhythmias treated with antiarrhythmic medications, had second-or third-degree atrioventricular block, had previous atrioventricular node ablation, had long-QT syndrome, or had renal failure that required dialysis. Patients had to be Ն18 years old, and women of childbearing potential had to use birth control.
Treatments for CHF were the same in both groups and included anticoagulants; the maximum tolerable dose of ␤-blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin-receptor antagonists; and implantable defibrillators, pacemakers, or ventricular resynchronization if indicated. The rhythm-control group received antiarrhythmic medications (most often amiodarone) and electrical cardioversion for AF recurrences. In the rate-control group, treatment with ␤-blockers and digoxin focused on maintaining a heart rate Ͻ80 bpm at rest and Ͻ110 bpm during a 6-minute walk test. Over a mean of 37 months, there were no differences in cardiovascular deaths or other study outcomes between groups.
Depression Measurement
Participants in sites with patients who spoke English, French, Spanish, Portuguese, or Danish completed valid translations of 20 items from the 21-item self-report BDI-II scale at baseline. Because of concerns about ensuring rapid psychiatric follow-up in a multinational context, the BDI-II item that assessed suicidal ideation was not administered. In our experience with other cardiac samples, this item has rarely been endorsed.
Outcome Measurement
The mean follow-up period for participants in the depression substudy was 39Ϯ18 months (range 24 to 74 months for survivors). Clinical variables and data on hospitalization and cardiac events were assessed at follow-up visits at 3 weeks and 4 months. Thereafter, patients were seen every 4 months through 4 years, followed by evaluations every 6 months. As in the overall study, the primary outcome for the present analyses was cardiovascular death. Two related secondary outcomes were also included: Arrhythmic death, because of the potential importance of proarrhythmic mechanisms in explaining links between depression and mortality, 17 and all-cause mortality, to facilitate comparison of results with other studies. An event adjudication committee, blinded to treatment group and depression status, classified all events.
Data Analysis
Analyses were performed with SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). Statistical tests were 2-tailed, with PՅ0.05 considered significant. Background comparisons between AF-CHF patients who did and did not complete the BDI-II and between those with elevated BDI-II scores (Ն14, the cut point used to indicate at least mild to moderate symptoms of depression on the BDI-II 15 ) and those with lower scores were conducted with 2 tests for categorical variables and t tests for continuous measures.
After proportionality assumptions were verified, Cox proportional hazards regression analyses were used to assess the prognostic importance of elevated depression symptoms both before and after covariate adjustment for the primary outcome (cardiovascular mortality) and for each of the 2 secondary outcomes (arrhythmic death and all-cause mortality). To assess the importance of increasing severity of depression symptoms, similar analyses were conducted with the standardized continuous BDI-II score. Patients receiving a heart transplant and those lost to follow-up were censored on the last day known to be living or free of heart transplant.
Data set-specific and stepwise approaches to covariate selection can produce unstable models that are not replicable. 18 Therefore, we used the approach for covariate selection outlined by Steyerberg et al. 18 All baseline variables were entered together into separate multivariable regression analyses to predict each of the primary and secondary outcomes. Variables with adjusted PϽ0.50 were retained as covariates and entered together into separate Cox regression analyses to predict the outcome in question, followed by the variable of elevated depression symptoms or the standardized BDI-II score. The significance of the addition of depression to the multivariable models was assessed with the likelihood ratio test. Because baseline depression was assessed Ն1 day after the study site received its randomization code for 85 of the participants (8.7%), and 1 report has suggested that this timing can influence self-report scores, 19 we assessed the role of timing of the BDI-II measure in predicting the primary and secondary study outcomes.
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Results
Some 974 (78.7%) of 1238 eligible substudy participants completed the baseline BDI-II. Those who did not complete the BDI-II were older, more likely to have symptomatic New York Heart Association functional class (Ͼ2), and more likely to have been hospitalized for CHF in the past 6 months. This pattern of differences was similar in the rhythm-and rate-control groups.
Participants were 66Ϯ11 years of age (range 24 to 94 years), and 17.7% were women. Overall, 32% had BDI-II scores Ն14 (at least mild to moderate symptoms of depression 15 ). Background characteristics of patients with and without elevated depression symptoms appear in Table 1 .
Participants with elevated depression symptoms were significantly more likely to be women, to be nonwhite, to be unmarried, and to have lower levels of education than those with lower levels of depression. They also were more likely to have been hospitalized for CHF in the 6 months before randomization, to have paroxysmal as opposed to persistent AF (and less likely to show AF on their baseline ECG), to have been treated previously with an antiarrhythmic agent, to have a New York Heart Association functional class Ͼ2, and to be taking an aldosterone antagonist. There were no differences in hypertension, diabetes mellitus, body mass index, creatinine level, left ventricular ejection fraction, or concomitant medical therapies at baseline (except for aldo-sterone antagonists). Finally, although the depressed participants were less likely to be in AF at baseline and at the 3-week visit than the nondepressed participants, there were no depression-related differences during follow-up in the proportion in sinus rhythm in either the rhythm-or ratecontrol groups (all PϾ0. 24) .
During the course of follow-up, 10 patients received heart transplants, and 36 were lost to follow-up. There was no difference between patients with and without elevated depression symptoms in the percentages transplanted (Pϭ0.40) or lost to follow-up (Pϭ0. 35) .
As shown in Table 2 , both elevated BDI-II scores and depression scores assessed as a continuous variable significantly predicted cardiovascular death, as well as the secondary outcomes of arrhythmic death and all-cause mortality.
None of the interactions between the BDI-II and treatment group (rhythm versus rate control) were significant (all PϾ0.60).
Survival curves for cardiovascular death associated with elevated BDI-II scores in each treatment group appear in Figure 1 . Older age, being unmarried, having diabetes mellitus, lower body mass index, higher creatinine level, ischemic cause of CHF, lower left ventricular ejection fraction, hospitalization for CHF within 6 months prior to randomization, lack of prior hospitalization for AF, having a New York Heart Association classification Ͼ2, taking long-acting nitrates, taking aldosterone antagonists, not taking ACE inhibitors, not taking ␤-blockers, and not taking oral anticoagulants all predicted cardiovascular mortality (see online-only Data Supplement). The timing of the baseline depression measure was not significantly related to the primary or secondary outcomes (all PϾ0. 15) , and none of the interactions between the BDI-II and baseline timing were significant (all PϾ0. 35) .
Covariate adjustment made little difference in the hazard ratios for the links between depression and cardiovascular mortality or between depression and either of the secondary outcomes (arrhythmic death and all-cause mortality). After adjustment for other baseline factors, elevated depression symptoms predicted a 57% increase in the hazard ratio for cardiovascular death, and there was a 27% increase in hazard ratio per 1-SD increase in scores on the BDI-II scale (equivalent to a 2% to 3% increase in hazard ratio per point increase on the scale). Table 3 shows the multivariable model for time to cardiovascular death. Values are hazard ratio (95% CI). *Adjusted for age, nonwhite race, marital status, previous transient ischemic attack or stroke, creatinine level, ischemic cause of CHF, left ventricular ejection fraction, paroxysmal AF, time since first diagnosis of AF Ͼ6 months, prior hospitalization for AF, prior electrical conversion, NYHA class Ͼ2, baseline ECG in AF, and baseline therapy of digoxin, ␤-blockers, long-acting nitrates, ACE inhibitors, oral anticoagulants, aldosterone antagonists, and lipid-lowering drugs.
†Adjusted for nonwhite race, marital status, creatinine level, ischemic cause of CHF, paroxysmal AF, prior hospitalization for AF, prior electrical conversion, previous antiarrhythmic agent, NYHA class Ͼ2, baseline ECG in AF, and baseline therapy of implantable cardioverter defibrillator, digoxin, ␤-blockers, long-lasting nitrate, ACE inhibitors, aldosterone antagonists, oral anticoagulants, and study treatment.
‡Adjusted for age, nonwhite race, marital status, diabetes mellitus, creatinine level, ischemic cause of CHF, paroxysmal AF, prior hospitalization for AF, prior electrical conversion, baseline ECG in AF, and baseline therapy of implantable cardioverter defibrillator, digoxin, ␤-blockers, long-acting nitrates, ACE inhibitors, aldosterone antagonists, lipid-lowering drugs, oral anticoagulants, and study treatment.
§Hazard ratio per SD (per 7.9 points on a scale of 0 to 60). 
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Although depressed patients were less likely to be married than nondepressed patients, elevated depression symptoms and marital status both significantly predicted time to cardiovascular death, even after adjustment for each other and for covariates. The interaction between the 2 factors was not significant (Pϭ0.85). Being married was associated with a decreased risk, and elevated depression symptoms predicted an increase in risk. However, there were no differences between the married and unmarried participants in the percentage of patients in sinus rhythm at any follow-up visit in either the rate-or rhythm-control groups (all PϾ0.18).
The survival curves for groups based on the combination of depression and marital status are illustrated in Figure 2 . Similar patterns occurred for arrhythmic death and all-cause mortality (data not shown).
Discussion
Although several studies have reported the prevalence and prognostic importance of depression in CHF patients (see Rutledge et al 20 and Pelle et al 21 for reviews), this is the first study of depression in patients with comorbid AF and CHF. After adjustment for many prognostic indicators, elevated depression symptoms significantly predicted cardiovascular mortality in both the rhythm-and rate-control treatment groups. The covariate-adjusted depression-related increase in hazards for cardiovascular death was similar to the increases associated with not taking oral anticoagulants and being prescribed aldosterone antagonists, important treatment factors likely to reflect disease severity.
CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) 22 found that depression significantly predicted sudden cardiac death in placebo-treated patients but not in those receiving amiodarone. Although 82% to 86% of the rhythm-control group in the present study took amiodarone during the first year compared with 3% to 7% of the rate-control patients, we observed no rhythm-versus ratecontrol difference in the link between elevated depression symptoms and arrhythmic death, which makes it unlikely that amiodarone is of particular value in preventing arrhythmic events in depressed patients.
Rutledge and colleagues 20 conducted a meta-analysis of 8 studies of depression in CHF patients published before September 2005 and reported a depression-related doubling in risk of poor cardiac prognosis (all-cause mortality plus "associated cardiac events"). Although most studies found that the prognostic importance of depression remained after adjustment for a limited group of covariates (usually age and New York Heart Association classification or ejection fraction), the pooled number of deaths was only 239. Most individual sample sizes were too small to allow for adequate adjustment for relevant background variables.
Several additional publications have appeared since this meta-analysis. [23] [24] [25] [26] [27] [28] [29] The largest followed up 1006 hospitalized CHF patients for an average of 2.6 years, during which 428 patients died. 29 Participants completed the Beck Depression Inventory (BDI-I) during admission. Consistent with the present findings, elevated depression scores significantly increased the hazard ratio for all-cause mortality (1.40; 95% CI 1.12 to 1.74, Pϭ0.003) after adjustment for multiple clinical and demographic variables. Like Jiang et al, 29 we found that although elevated depression symptoms were linked to New York Heart Association classification, there was no relationship with more objective measures, including left ventricular ejection fraction. Depressed individuals may be less likely to provide maximal effort during evaluations such as exercise stress tests that require patient collaboration. 30 They may also perceive and report more symptoms of dysfunction, leading physicians to classify them as more severely impaired than objective measures would suggest. Finally, as in the present results, Jiang et al 29 reported that elevated depression symptoms and being unmarried significantly predicted all-cause mortality even when both were included in the same multivariable model; however, no other outcomes were assessed, and the percentage of patients with AF was not described.
In addition to their prognostic importance for all-cause mortality, we found that elevated depression symptoms and marital status had additive predictive value for cardiovascular deaths and arrhythmic deaths, with the greatest risk in those who were both depressed and unmarried. We also observed that the depressed were more likely to be unmarried than the nondepressed. However, depression did not explain the risk associated with being unmarried, and marital status did not explain the risk associated with depression. They do not appear to be redundant markers of risk.
There have been multiple reports of the relationship between marital status and survival in the general community, 31 as well as in patients with CAD 32 and CHF. 33 More complex indicators of social support, including the size of the social network, have also predicted outcomes 34 ; however, none of these were included in the present study.
Married individuals and those with better social support may be more likely to adhere to recommended treatments and lifestyle changes. 35 Others have suggested that social support affects neuroendocrine, platelet, and immune parameters similar to those hypothesized to explain the prognostic importance of depression. 36, 37 A recent large case-control study of out-of-hospital cardiac arrests found that both clinical depression and marital status significantly predicted cardiac arrests in subjects with and without preexisting CAD, even after adjustment for other risks. 38, 39 As we observed, depression and marital status contributed additive risks, with depressed patients who were unmarried being at highest risk of cardiac arrest. In conjunction with the present secondary outcome results relative to arrhythmic deaths, this suggests that an arrhythmic mechanism may be important in explaining the depression-and marital status-related increases in risk observed in the present study. Depression may be associated with changes in parasympathetic/sympathetic balance that can lower the arrhythmic threshold, 17 particularly in the presence of cardiac disease or conditions, such as CHF, associated with increased sympathetic activity. Similar autonomic imbalance may extend to other chronic stress situations, including living with severe cardiac disease without the support of a partner. Additional exploration of mechanisms underlying these relationships is warranted.
Study Limitations
In this first study of the prognostic importance of depression in CHF patients with AF, we used a psychometrically sound measure of depression symptoms and included a large international sample of patients followed up for a mean of 39 months. Because patients were enrolled in a clinical trial, results cannot be generalized to all CHF patients with AF. Participants received optimal medical management and were highly compliant with treatment, which limited the plausibility of noncompliance and/or inadequate medical treatment as explanations for the predictive importance of depression. Because clinician ratings were not feasible in this large multinational trial, we used a self-report measure of depression symptoms. We recently reported that standardized clinician ratings have stronger prognostic importance in stable CAD patients than self-reports 40 and that most of the risk associated with elevated symptom levels is accounted for by those who meet psychiatric diagnostic criteria. It is likely that the depression-related increases in hazards reported here would have been larger if we had used clinician ratings. Depression was measured only 1 time, before randomization, and we do not know how changes in depression may have influenced results; however, repeated assessment was not feasible in this multinational study. In fact, few epidemiological studies have addressed the prognostic importance of changes in depression for cardiac prognosis, and no clinical trial has demonstrated that changes in depression alter event rates in any group of cardiac patients. 6 We also have no data on the use of antidepressant medications in AF-CHF trial participants. Finally, the number of participants in most of the participating countries was too small to allow for assessment or statistical control of country-specific factors.
Conclusions
Both elevated depression symptoms and living without a marital partner emerged as clear indicators of poor prognosis in CHF patients with AF and added significantly to the ability of more established indicators to identify patients at greatest risk. The American Heart Association 41 recently recommended depression screening in CAD patients to identify those who might benefit from additional evaluation or treatment, and there is evidence that selective serotonin reuptake inhibitor antidepressant medications are as safe and efficacious in CAD patients as in the nonmedically ill. In the absence of clinical trials specifically addressing these psychosocial risks among CHF patients with AF, we believe that depression and lack of a marital partner should be considered as risk markers identifying patients who may require additional treatment efforts to manage their cardiac conditions and modify other known risks.
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